Oncology Research

 
Stock Quotes for Oncology Research top ^
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Type: Speculative Growth
Sign-up for csbr investment picks
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Small Core
  • Stock Type: Speculative Growth
Sign-up for ziop investment picks
  • Industry: Diagnostics & Research
  • Sector: Healthcare
  • Stock Type: Distressed
Sign-up for avto investment picks
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Small Growth
  • Stock Type: Distressed
Sign-up for clvs investment picks
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Small Core
  • Stock Type: Speculative Growth
Sign-up for ziop investment picks
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Small Growth
  • Stock Type: Distressed
Sign-up for clvs investment picks
  • Industry: Medical Care
  • Sector: Healthcare
  • Stock Type: Distressed
Sign-up for roix investment picks

 
News Articles for Oncology Research top ^
SAN DIEGO , May 14, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV) , a developer of cell-free molecular diagnostics, today announced that data from a study of its precision cancer monitoring technology, conducted by MD Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center, will be presented during a poster session at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO). An additional abstract, submitted by Filip Janku , M.D., Ph.D., of The University of Texas MD Anderson Cancer, has been accepted for publication in 2014 ASCO Annual Meeting Proceedings , a Journal of Clinical Oncology.
Sign-up for Trovagene Announces Data Presentations, Published Abstracts at Annual Meeting of American Society of Clinical Oncology investment picks
NEW YORK, April 17, 2014 (GLOBE NEWSWIRE) -- Harris & Harris Group, Inc. (Nasdaq:TINY) , an investor in transformative companies enabled by disruptive science, released its blog post on Champions Oncology and why it is on the cutting edge of personalized medicine.
Sign-up for Harris & Harris Group Continues Its Blog Series to Highlight Most Impactful Portfolio Companies With Champions Oncology, Inc. investment picks
PORTLAND, Ore., May 21, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE) , a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that data from the Company's Phase 1 study with GALE-301, or Folate Binding Protein, will be presented at the upcoming American Society of Clinical Oncology (ASCO) 50 th Annual Meeting.
Sign-up for Galena Biopharma to Present GALE-301 Phase 1 Data at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting investment picks
Grant Earmarked for Trial Drug Aimed at Treatment of Anal Cancer LOS ANGELES , April 30, 2014 /PRNewswire/ -- The Farrah Fawcett Foundation (FFF) has presented a $50,000 grant to the Brown University Oncology Research Group (BrUOG) for "BrUOG 276: A Phase II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer," it was announced by Alana Stewart , President of The FFF.
Sign-up for Farrah Fawcett Foundation Announces $50,000 Grant To Brown University Oncology Research Group investment picks
2014/5/4
Alliance of Australian and U.S. researchers and children's cancer advocates focused on developing drugs as potential treatments for neuroblastoma, the most common solid form of childhood cancer SYDNEY and COLUMBUS, Ohio , May 4, 2014 /PRNewswire/ -- Researchers and children's cancer advocates in Australia and the U.S. have formed a unique research and development alliance to facilitate development of treatments for children fighting neuroblastoma, the most common and fatal form of solid cancer affecting infants.
Sign-up for Children's Oncology Drug Alliance (CODA) Formed to Facilitate Development of Treatments for Childhood Cancers investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Oncology Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Omega Healthcare Investors  |  Next: One Analyst